Gastrointestinal Cancer | Specialty

Emergency Management of Chemotherapy Toxicity

May 30th 2017

Severe Early-Onset Toxicities From 5-FU or Capecitabine

May 30th 2017

5-FU or Capecitabine Toxicity Patient Education

May 30th 2017

Chemotherapy Overdose of 5-FU or Capecitabine

May 30th 2017

Nursing Perspective of Early-Onset Severe Toxicities

May 30th 2017

Early-Onset Toxicities from 5-FU and Capecitabine

May 30th 2017

Chemotherapy for Metastatic Colorectal Cancer in 2017

May 30th 2017

Dr. Strosberg on Understanding the Current Field of Neuroendocrine Tumors

May 26th 2017

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, shares his insight on the current field of neuroendocrine tumors (NETs).

FDA Grants Nivolumab Priority Review for Liver Cancer

May 26th 2017

The FDA has granted a priority review designation to nivolumab (Opdivo) for use as a treatment for patients with hepatocellular carcinoma following prior sorafenib (Nexavar).

FDA Grants Pembrolizumab Priority Review for Advanced Gastric Cancer

May 24th 2017

The FDA has granted a priority review to a supplemental Biologics License Application for pembrolizumab (Keytruda) for the treatment of patients who have undergone at least 2 courses of chemotherapy for recurrent or advanced gastric or gastroesophageal junction adenocarcinoma.

Dr. Di Costanzo on the Effectiveness of Sorafenib in HCC

May 24th 2017

Giovan Giuseppe Di Costanzo, MD, Cardarelli Hospital, discusses a scoring system to predict the effectiveness of sorafenib (Nexavar) in hepatocellular carcinoma (HCC).

Dr. Grothey on FDA Approval of Pembrolizumab in MSI-High CRC

May 24th 2017

Axel Grothey, MD, medical oncologist at Mayo Clinic, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with microsatellite instability-high colorectal cancer (CRC).

Dr. Sears on Ongoing Research of Microbiota in CRC

May 24th 2017

Cynthia L. Sears, MD, professor of Medicine, at Johns Hopkins University School of Medicine, member of the Bloomberg-Kimmel Institute for Cancer Immunotherapy, discusses ongoing research of microbiota for patients with colorectal cancer (CRC).

FDA Approves Pembrolizumab for Microsatellite Instability-High and Mismatch Repair Deficient Cancers

May 23rd 2017

The FDA has granted an accelerated approval to pembrolizumab (Keytruda) for the treatment of patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed after prior treatment and who have no satisfactory alternative treatment options, as well as for patients with MSI-H or dMMR colorectal cancer following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.

Dr. Greten on Promising Immunotherapy Agents in HCC

May 19th 2017

Tim F. Greten, MD, senior investigator thoracic and gastrointestinal oncology branch, head, gastrointestinal malignancy section, National Cancer Institute, discusses promising immunotherapy agents being investigated in hepatocellular carcinoma (HCC).

Challenges Facing the Future of Cholangiocarcinoma

May 19th 2017

Jesper Andersen, PhD, associate professor, Biotech and Innovation Centre, University of Copenhagen, discusses the challenges facing the future treatment of patients with cholangiocarcinoma.

Adopting Healthy Lifestyle Leads to Improved Overall Survival in Postsurgical Colon Cancer

May 18th 2017

Patients with stage III colorectal cancer who maintained a healthy body weight, engaged in regular physical activity, and adopted other healthy lifestyle behaviors experienced a 42% lower chance of death and a trend toward reduced cancer recurrence.

Eating Nuts After Colon Cancer Improves Survival and Lowers Recurrence Risk

May 18th 2017

Findings of a new prospective study suggest that eating tree nuts like almonds, walnuts, and pecans can improve overall survival and reduce the risk of recurrence in patients with colon cancer.

Adjuvant Capecitabine Improves Survival in Biliary Tract Cancer

May 17th 2017

Treatment with adjuvant capecitabine improved overall survival by 15 months compared with observation alone for patients with macroscopically resected biliary tract cancer, according to findings from the phase III BILCAP study released in advance of the 2017 ASCO Annual Meeting.

Genomic Findings Reshaping CRC Field

May 16th 2017

Extensive studies into molecular aberrations in colorectal cancer are yielding fresh insights into the potential clinical utility of checkpoint immunotherapies, genetic testing, and tumor-sidedness implications. Experts weigh in on key developments that may change treatment paradigms.